急性B淋巴细胞白血病的免疫表型表达特征及临床意义
发布时间：2018-08-26 16:41
【摘要】：目的:探讨急性B淋巴细胞白血病(B-ALL)免疫表型表达特征及临床意义。方法:采用流式细胞术(FMC)对初诊的50例BCR-ABL融合基因阴性的急性B淋巴细胞白血病患者进行免疫分型。观察急性B淋巴细胞白血病的免疫表型表达特征及临床意义。结果:50例患者中,B细胞抗原中CD19+表达率为84.00%,阳性表达率最高。T细胞抗原CD5、CD7可跨系表达。伴髓系抗原中CD13+表达率最高,表达率为48.00%。50例患者入院确诊后均进行诱导化疗,第一次化疗后完全缓解(CR1)率为76.00%,总有效率为86.00%。男性患者第一次化疗后CR1率为77.27%,总有效率为95.45%,女性CR1率及总有效率分别为75.00%、78.57%,男女两组CR1率、总有效率比较不具备统计学差别。依据年龄分为≥40岁和40岁两组,第一次化疗后≥40岁组CR1率为57.14%,总有效率71.42%,40岁组CR1率为89.65%,总有效率为96.55%,≥40岁组CR1率、总有效率均低于40岁组,比较具备统计学差别。依据贫血严重程度可以将所有患者分成轻度贫血组和中重度贫血组,首次化疗后轻度贫血组CR1率为100%,总有效率100%,中重度贫血组CR1率为62.50%,总有效率为78.12%,两组之间CR1率、总有效率分别比较,轻度贫血组都高于中重度贫血组,具备统计学差别。29例CD10+组患者首次化疗后CR1率为86.20%,总有效率为96.55%,21例CD10-组CR1率为61.90%,总有效率71.42%,CD10-组完全缓解率、总有效率都低于CD10+组,具备统计学差异。26例CD20+组患者首次化疗后CR1率为57.69%,总有效率为73.08%,24例CD20-组患者第一次化疗后完全缓解率为95.83%,总有效率100%,CD20-组的CR1率、总有效率都高于CD20+组,具备统计学意义。24例CD13+组患者首次化疗后CR1率为62.50%,总有效率为70.83%,26例CD13-组患者CR率为88.46%,总有效率100%,CD13+组完全缓解率、总有效率均低于CD13-组,统计学比较存在差异。11例CD33+组患者首次化疗后CR1率为45.45%,总有效率为54.54%,37例CD33-组患者CR1率为86.48%,总有效率94.59%,CD33+组完全缓解率、总有效率均低于CD33-组,统计学比较有差异。25例CD34+组患者首次化疗后CR1率为64.00%,总有效率为72.00%,20例CD34-组患者CR1率为95.00%,总有效率100%,CD34+组完全缓解率、总有效率均低于CD34-组,统计学比较有差异。15例CD96+组患者首次化疗后CR1率为46.66%,总有效率为60.00%,16例CD96-组患者CR1率为87.50%,总有效率93.75%,CD96-组的CR1率、总有效率均高于CD96+组,具备统计学差别。29例My+B-ALL组患者中有首次化疗后CR1率为65.51%,总有效率为75.86%,21例My-B-ALL组患者中首次化疗后CR1率为90.47%,总有效率100%,My-B-ALL组CR1率、总有效率两者都高于My+B-ALL组,统计学比较有差异。CD34/CD13抗原共表达组占总例数的20.00%,CD34/CD33共表达组占总例数的14.00%,CD34/CD96共表达组占总例数的18.00%。CD34/CD13抗原共表达组和非共表达组的CR1率分别是30.00%,86.20%,其总有效率分别是30.00%,100%。CD34/CD33抗原共表达组和非共表达组的CR1率分别是28.57%,77.27%,其总有效率分别是28.57%,90.90%。CD34/CD96抗原共表达组和非共表达组的CR1率分别是22.22%,86.36%,其总有效率分别是33.33%,95.45%。CD34/CD13抗原共表达组CR1率、总有效率均明显低于CD34/CD13非共表达组,具备显著统计学意义。CD34/CD33共表达组的CR1率、总有效率均低于CD34/CD33非共表达组,具备统计学意义。CD34/CD96共表达组的CR1率、总有效率均低于CD34/CD96非共表达组,具备统计学意义。结论:1.CD19是B-ALL的敏感性、特异性抗原;CD7、CD5可跨系表达于B-ALL;B-ALL伴髓系抗原中CD13阳性率最高。2.性别对B-ALL临床疗效无影响;年龄是影响B-ALL临床疗效的因素;初诊时贫血严重程度是影响B-ALL临床疗效的因素。3.CD10+与B-ALL临床疗效呈正相关,免疫表型CD20+、CD13+、CD33+、CD34+、CD96+均与B-ALL临床疗效呈负相关。4.My+B-ALL临床疗效差;抗原CD34/CD13、CD34/CD33、CD34/CD96共表达与B-ALL临床疗效呈负相关。
[Abstract]:Objective: To investigate the immunophenotypic characteristics and clinical significance of acute B-lymphoblastic leukemia (B-ALL). Methods: Immunophenotyping of 50 newly diagnosed patients with BCR-ABL fusion gene negative acute B-lymphoblastic leukemia was performed by flow cytometry (FMC). Results: The expression rate of CD19+ in B cell antigen was 84.00% and the positive rate was the highest. T cell antigen CD5 and CD7 could be expressed across lines. The expression rate of CD13+ in myeloid antigen was the highest (48.00%). After the first chemotherapy, the CR1 rate was 77.27%, the total effective rate was 95.45%, the female CR1 rate and the total effective rate were 75.00% and 78.57%, respectively. According to the severity of anemia, all patients can be divided into mild anemia group and moderate and severe anemia group. After the first chemotherapy, the CR1 rate of mild anemia group is 100%, the total effective rate is 100%, and the CR1 rate of moderate and severe anemia group is 62.50%. The total effective rate was 96.55%. The CR1 rate was 61.90%. The total effective rate was 71.42%. The total effective rate of CD10-group was lower than that of CD10+group. The total effective rate was 73.08%. The total effective rate was 95.83%. The total effective rate was 100%. The total effective rate was higher in the CD20 group than that in the CD20 + group. The total effective rate was 62.50% in the CD13 + group. The total effective rate was 100%. The total effective rate of CD13 + group was lower than that of CD13 - group. The total effective rate was 45.45%. The total effective rate was 54.54%. The total effective rate was 86.48%. The total effective rate was 94.59%. The total effective rate of CD33 + group was lower than that of CD13 - group. The CR1 rate was 64.00%, the total effective rate was 72.00%, the CR1 rate was 95.00%, the total effective rate was 100%, the total effective rate was 100%, and the total effective rate was lower in the CD34 + group than in the CD34 - group. The CR1 rate in the CD96 + group was 46.6% after the first chemotherapy. The total effective rate was 60.00%. The total effective rate was 87.50% and 93.75% in 16 patients with CD96-group. The total effective rate of CD96-group was higher than that of CD96+group. The total effective rate was 65.51% and 75.86% in 29 patients with My+B-ALL after the first chemotherapy. The total effective rate was 90.47% and 1.47% in 21 patients with My-B-ALL after the first chemotherapy. The CR1 rate and total effective rate in my-B-ALL group and my-B-ALL group were higher than those in my+B-ALL group. The CR1 rate of CD34/CD13 antigen co-expression group accounted for 20.00%, CD34/CD33 co-expression group accounted for 14.00%, CD34/CD96 co-expression group accounted for 18.00% and CD34/CD96 co-expression group accounted for 30.00% and 86.20% respectively. The total effective rates were 30.00% and 100%, respectively. The CR1 rates of CD34/CD33 co-expression group and non-co-expression group were 28.57% and 77.27%, respectively. The total effective rates were 28.57% and 90.90% respectively. The CR1 rates of CD34/CD96 co-expression group and non-co-expression group were 22.22% and 86.36% respectively. The total effective rates were 33.33% and 95.45% respectively. The total effective rate of the CD34/CD33 co-expression group was lower than that of the CD34/CD13 non-co-expression group. The total effective rate of the CD34/CD33 co-expression group was lower than that of the CD34/CD33 non-co-expression group. The total effective rate of the CD34/CD96 co-expression group was lower than that of the CD34/CD96 non-co-expression group. CD7 and CD5 can be expressed in B-ALL; CD13 positive rate is the highest in B-ALL with myeloid antigen. 2. Gender has no effect on clinical efficacy of B-ALL; age is the factor affecting clinical efficacy of B-ALL; anemia severity is the factor affecting clinical efficacy of B-ALL at initial diagnosis. 3. CD10 + is positively correlated with clinical efficacy of B-ALL, and immunophenotype is the highest. CD20 +, CD13 +, CD33 +, CD34 +, CD96 + were negatively correlated with the clinical efficacy of B-ALL. 4. My + B-ALL had poor clinical efficacy; the co-expression of antigen CD34/CD13, CD34/CD33, CD34/CD96 was negatively correlated with the clinical efficacy of B-ALL.
【学位授予单位】：延安大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R733.71
本文编号：2205521
[Abstract]:Objective: To investigate the immunophenotypic characteristics and clinical significance of acute B-lymphoblastic leukemia (B-ALL). Methods: Immunophenotyping of 50 newly diagnosed patients with BCR-ABL fusion gene negative acute B-lymphoblastic leukemia was performed by flow cytometry (FMC). Results: The expression rate of CD19+ in B cell antigen was 84.00% and the positive rate was the highest. T cell antigen CD5 and CD7 could be expressed across lines. The expression rate of CD13+ in myeloid antigen was the highest (48.00%). After the first chemotherapy, the CR1 rate was 77.27%, the total effective rate was 95.45%, the female CR1 rate and the total effective rate were 75.00% and 78.57%, respectively. According to the severity of anemia, all patients can be divided into mild anemia group and moderate and severe anemia group. After the first chemotherapy, the CR1 rate of mild anemia group is 100%, the total effective rate is 100%, and the CR1 rate of moderate and severe anemia group is 62.50%. The total effective rate was 96.55%. The CR1 rate was 61.90%. The total effective rate was 71.42%. The total effective rate of CD10-group was lower than that of CD10+group. The total effective rate was 73.08%. The total effective rate was 95.83%. The total effective rate was 100%. The total effective rate was higher in the CD20 group than that in the CD20 + group. The total effective rate was 62.50% in the CD13 + group. The total effective rate was 100%. The total effective rate of CD13 + group was lower than that of CD13 - group. The total effective rate was 45.45%. The total effective rate was 54.54%. The total effective rate was 86.48%. The total effective rate was 94.59%. The total effective rate of CD33 + group was lower than that of CD13 - group. The CR1 rate was 64.00%, the total effective rate was 72.00%, the CR1 rate was 95.00%, the total effective rate was 100%, the total effective rate was 100%, and the total effective rate was lower in the CD34 + group than in the CD34 - group. The CR1 rate in the CD96 + group was 46.6% after the first chemotherapy. The total effective rate was 60.00%. The total effective rate was 87.50% and 93.75% in 16 patients with CD96-group. The total effective rate of CD96-group was higher than that of CD96+group. The total effective rate was 65.51% and 75.86% in 29 patients with My+B-ALL after the first chemotherapy. The total effective rate was 90.47% and 1.47% in 21 patients with My-B-ALL after the first chemotherapy. The CR1 rate and total effective rate in my-B-ALL group and my-B-ALL group were higher than those in my+B-ALL group. The CR1 rate of CD34/CD13 antigen co-expression group accounted for 20.00%, CD34/CD33 co-expression group accounted for 14.00%, CD34/CD96 co-expression group accounted for 18.00% and CD34/CD96 co-expression group accounted for 30.00% and 86.20% respectively. The total effective rates were 30.00% and 100%, respectively. The CR1 rates of CD34/CD33 co-expression group and non-co-expression group were 28.57% and 77.27%, respectively. The total effective rates were 28.57% and 90.90% respectively. The CR1 rates of CD34/CD96 co-expression group and non-co-expression group were 22.22% and 86.36% respectively. The total effective rates were 33.33% and 95.45% respectively. The total effective rate of the CD34/CD33 co-expression group was lower than that of the CD34/CD13 non-co-expression group. The total effective rate of the CD34/CD33 co-expression group was lower than that of the CD34/CD33 non-co-expression group. The total effective rate of the CD34/CD96 co-expression group was lower than that of the CD34/CD96 non-co-expression group. CD7 and CD5 can be expressed in B-ALL; CD13 positive rate is the highest in B-ALL with myeloid antigen. 2. Gender has no effect on clinical efficacy of B-ALL; age is the factor affecting clinical efficacy of B-ALL; anemia severity is the factor affecting clinical efficacy of B-ALL at initial diagnosis. 3. CD10 + is positively correlated with clinical efficacy of B-ALL, and immunophenotype is the highest. CD20 +, CD13 +, CD33 +, CD34 +, CD96 + were negatively correlated with the clinical efficacy of B-ALL. 4. My + B-ALL had poor clinical efficacy; the co-expression of antigen CD34/CD13, CD34/CD33, CD34/CD96 was negatively correlated with the clinical efficacy of B-ALL.
【学位授予单位】：延安大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R733.71
【参考文献】
相关期刊论文 前10条
1 丁利娟;黄河;;CD19-CAR-T细胞治疗难治复发急性淋巴细胞白血病的研究进展[J];中国肿瘤生物治疗杂志;2017年01期
2 沈伟;韦永琼;于霞;罗德幸;刘成桂;;儿童急性淋巴细胞白血病MICM检测结果分析[J];检验医学与临床;2016年19期
3 石连霞;;急性淋巴细胞白血病微小残留病诊断研究进展[J];临床检验杂志;2016年09期
4 张向臣;刘卫华;张秀莲;;CD20在成人急性B淋巴细胞白血病中的表达价值[J];中国卫生标准管理;2016年05期
5 王艳;王军;熊学艳;郑晓敏;;CD34、CD38抗原在儿童急性白血病中的表达意义[J];南通大学学报(医学版);2016年01期
6 马平;田亮;刘炜;王小稳;;CD20阳性表达及与儿童急性B淋巴细胞白血病预后相关性研究[J];医药论坛杂志;2015年11期
7 王晓雪;王萍萍;梁颖;李艳;颜晓菁;;成人急性淋巴细胞白血病免疫表型的特点分析[J];中国医科大学学报;2015年10期
8 周进;王婧;刘辉;郑慧菲;马玲;王攀峰;颜霜;傅t$t$;;B系急性淋巴细胞白血病中CD20表达及其对预后影响[J];中国实验血液学杂志;2015年03期
9 王会芳;苏显都;于彩霞;王家坡;王国增;王丽丽;张硕;李丽霞;李健;;125例成人急性髓系白血病免疫表型特点分析[J];解放军医学院学报;2015年04期
10 王毅捷;孙和顺;马亚震;;CD96及P选择素在急性白血病患者外周血中的表达及临床意义[J];血栓与止血学;2015年01期
相关硕士学位论文 前1条
1 吴颖;急性白血病患者造血干细胞CD96分子表达的初步研究[D];华中科技大学;2011年
，本文编号：2205521
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2205521.html